WO2012143141A3 - Compositions antivirales dirigees contre la nucleoproteine des virus influenza - Google Patents

Compositions antivirales dirigees contre la nucleoproteine des virus influenza Download PDF

Info

Publication number
WO2012143141A3
WO2012143141A3 PCT/EP2012/001720 EP2012001720W WO2012143141A3 WO 2012143141 A3 WO2012143141 A3 WO 2012143141A3 EP 2012001720 W EP2012001720 W EP 2012001720W WO 2012143141 A3 WO2012143141 A3 WO 2012143141A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
nucleoprotein
viral
property
compound
Prior art date
Application number
PCT/EP2012/001720
Other languages
English (en)
Other versions
WO2012143141A2 (fr
Inventor
Anny SLAMA SCHWOK
Bernard Delmas
Stéphane QUIDEAU
Hélène BERTRAND
Bogdan TARUS
Original Assignee
Institut National De La Recherche Agronomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Recherche Agronomique filed Critical Institut National De La Recherche Agronomique
Priority to US14/112,987 priority Critical patent/US9783482B2/en
Priority to EP12717604.8A priority patent/EP2699238A2/fr
Publication of WO2012143141A2 publication Critical patent/WO2012143141A2/fr
Publication of WO2012143141A3 publication Critical patent/WO2012143141A3/fr
Priority to US15/696,833 priority patent/US20180028478A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
    • C07C57/40—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic containing condensed ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une composition pharmaceutique destinée au traitement d'une infection virale par un virus Influenza de type A chez un sujet, laquelle composition comprend un composé ayant la propriété d'agir en tant qu'inhibiteur de la fixation de l'ARN viral à la nucléoprotéine des virus Influenza de type A, ledit composé ayant la propriété de se lier au domaine de liaison de l'ARN viral sur ladite nucléoprotéine. L'invention porte également sur une composition pharmaceutique destinée au traitement d'une infection virale par un Orthomyxo virus chez un sujet, laquelle composition comprend un composé ayant la propriété d'agir en tant qu'inhibiteur de la fixation de l'ARN viral à la nucléoprotéine des Orthomyxovirus, ledit composé ayant la propriété de se lier au domaine de liaison de l'ARN viral sur la nucléoprotéine desdits virus. L'invention porte en outre sur un composé ayant la propriété d'agir en tant qu'inhibiteur de la fixation de l'ARN viral à la nucléoprotéine des virus Influenza de type A, ledit composé ayant la propriété de se lier au domaine de liaison de l'ARN viral sur la nucléoprotéine des virus Influenza de type A et sur un procédé d'identification d'un composé ayant la propriété de se lier au niveau du domaine de liaison de l'ARN viral sur la nucléoprotéine des virus Influenza de type A.
PCT/EP2012/001720 2011-04-21 2012-04-20 Compositions antivirales dirigees contre la nucleoproteine des virus influenza WO2012143141A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/112,987 US9783482B2 (en) 2011-04-21 2012-04-20 Antiviral compositions directed against the influenza virus nucleoprotein
EP12717604.8A EP2699238A2 (fr) 2011-04-21 2012-04-20 Compositions antivirales dirigees contre la nucleoproteine des virus influenza
US15/696,833 US20180028478A1 (en) 2011-04-21 2017-09-06 Antiviral compositions directed against the nucleoprotein of influenza viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR1101253 2011-04-21
FR1101253A FR2974299A1 (fr) 2011-04-21 2011-04-21 Compositions antivirales dirigees contre la nucleoproteine des virus influenza

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/112,987 A-371-Of-International US9783482B2 (en) 2011-04-21 2012-04-20 Antiviral compositions directed against the influenza virus nucleoprotein
US15/696,833 Continuation-In-Part US20180028478A1 (en) 2011-04-21 2017-09-06 Antiviral compositions directed against the nucleoprotein of influenza viruses

Publications (2)

Publication Number Publication Date
WO2012143141A2 WO2012143141A2 (fr) 2012-10-26
WO2012143141A3 true WO2012143141A3 (fr) 2012-12-13

Family

ID=46022154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/001720 WO2012143141A2 (fr) 2011-04-21 2012-04-20 Compositions antivirales dirigees contre la nucleoproteine des virus influenza

Country Status (4)

Country Link
US (1) US9783482B2 (fr)
EP (1) EP2699238A2 (fr)
FR (1) FR2974299A1 (fr)
WO (1) WO2012143141A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107286133B (zh) * 2017-07-24 2019-05-10 湖南大学 3-芳基-1,2,4-三唑-5(4h)-硫酮亚胺作为na抑制剂的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124473A (en) * 1985-07-25 1992-06-23 Centre International De Recherches Dermatologiques Galderma (Cird Galderma) Polycyclic aromatic derivatives, process for preparing the same and pharmaceutical and cosmetic compositions containing the same
WO2005030224A1 (fr) * 2003-09-26 2005-04-07 Nicox S.A. Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale
WO2007134678A2 (fr) * 2006-05-18 2007-11-29 Merck Patent Gmbh Dérivés de triazole ii
WO2010143207A1 (fr) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Compositions orales à goût masqué d'antiviraux de grippe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1101253A (fr) 1954-03-18 1955-10-04 Tech Du Verre Tisse Procédés et produits pour raidir des matériaux minces en plastiques armés
US6333435B1 (en) * 1995-05-18 2001-12-25 Merck & Co., Inc. Process of synthesizing binaphthyl derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124473A (en) * 1985-07-25 1992-06-23 Centre International De Recherches Dermatologiques Galderma (Cird Galderma) Polycyclic aromatic derivatives, process for preparing the same and pharmaceutical and cosmetic compositions containing the same
WO2005030224A1 (fr) * 2003-09-26 2005-04-07 Nicox S.A. Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale
WO2007134678A2 (fr) * 2006-05-18 2007-11-29 Merck Patent Gmbh Dérivés de triazole ii
WO2010143207A1 (fr) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Compositions orales à goût masqué d'antiviraux de grippe

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"ZINC19861005", 12 November 2008 (2008-11-12), XP002684273, Retrieved from the Internet <URL:http://zink.docking.org/substance/19861005> [retrieved on 20120920] *
FEDICHEV PETER ET AL: "Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo.", PLOS CURRENTS 2011 LNKD- PUBMED:21894258, vol. 3, September 2011 (2011-09-01), pages RRN1253, XP007921094, ISSN: 2157-3999 *
GERRITZ SAMUEL W ET AL: "Optimization and biophysical characterization of small molecules that inhibit influenza virus replication via binding to nucleoprotein (NP)", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 241, March 2011 (2011-03-01), & 241ST NATIONAL MEETING AND EXPOSITION OF THE AMERICAN-CHEMICAL-SOCIETY (ACS); ANAHEIM, CA, USA; MARCH 27 -31, 2011, pages 20 - MEDI, XP009155908, ISSN: 0065-7727 *
RICHARD Y KAO ET AL: "Identification of influenza A nucleoprotein as an antiviral target", NATURE BIOTECHNOLOGY, vol. 28, no. 6, 30 May 2010 (2010-05-30), pages 600 - 605, XP055009857, ISSN: 1087-0156, DOI: 10.1038/nbt.1638 *
SIDDIQUI SHADAB MIYAN ET AL: "Thiosemicarbazone fragment embedded within 1,2,4-triazole ring as inhibitors of Entamoeba histolytica", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 8, April 2012 (2012-04-01), pages 2768 - 2771, XP002684275 *
YE Q ET AL: "The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA", NATURE 20061221 GB LNKD- DOI:10.1038/NATURE05379, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1078 - 1082, XP007920157, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
US9783482B2 (en) 2017-10-10
US20140163107A1 (en) 2014-06-12
EP2699238A2 (fr) 2014-02-26
FR2974299A1 (fr) 2012-10-26
WO2012143141A2 (fr) 2012-10-26

Similar Documents

Publication Publication Date Title
IL284578A (en) Double-stranded RNA suppressors of the hepatitis B virus, preparations containing them and their uses
IL244597B (en) Replication suppressors of influenza viruses, preparations containing them and their uses
GT201300293A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina.
WO2007053696A3 (fr) Inhibition de la replication du virus de la grippe par interference arn
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
WO2013040492A3 (fr) Procédés permettant de traiter le virus de l&#39;hépatite c (hcv)
CY1118567T1 (el) Αναστολεις του ιου της ηπατιτιδας c
AP2012006067A0 (en) Inhibitors of influenza viruses replication.
DK2242752T3 (da) Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
WO2010095041A3 (fr) Compositions, procédés et kits pour traiter des infections par le virus de la grippe
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
WO2009136979A3 (fr) Composés qui modulent la réplication du virus à arn simple brin, sens négatif, et leurs utilisations
BR112015007879A2 (pt) inibidores do vírus da hepatite c
BR112013032049A2 (pt) inibidores do vírus da hepatite c
SG179082A1 (en) Method for the preparation of an influenza virus
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
EP2444095A4 (fr) Inhibiteur d&#39;une infection par un virus à arn, procédé d&#39;inhibition d&#39;une infection par un virus à arn, produits pour l&#39;inhibition d&#39;une infection par un virus à arn et utilisation en tant qu&#39;inhibiteur d&#39;une infection par un virus à arn
WO2012162580A3 (fr) Composés antiviraux
WO2012162578A3 (fr) Composés antiviraux
WO2011056630A3 (fr) Inhibiteurs du virus de l&#39;hépatite c se présentant sous la forme de petites molécules
MX363464B (es) Vacunas contra influenza h5.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12717604

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012717604

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14112987

Country of ref document: US